Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q2 2026 Earnings Presentation
17 slides from Hls Therapeutics's earnings presentation, Aug 12, 2026
Slide 1: Q2 2026 Earnings Call – August 12, 2026
Q2 2026 Earnings Call – August 12, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements contained in this presentation. These factors should be considered statements that express or involve discussions with respect to predictions, carefully and prospective investors shoul
Slide 3: Q2 Big Picture
Q2 Big Picture 01 02 03 Acceleration of Signs of Clozaril Strongest balance cardiovascular business stabilizing sheet in years growth engine in Canada Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual result
Slide 4: Cardiovascular Portfolio Growth Accelerating
Cardiovascular Portfolio Growth Accelerating Cardiovascular portfolio net sales growth (millions) CAD Vascepa NILEMDO reimbursement secured 8 NILEMDO with largest private payers in Canada 6 25% 4 Unanimous recommendation for 2 NILEMDO public reimbursement from Canada’s Drug Agency 0 Q2 2025 Q2 2026
Slide 5: Balanced Capital Allocation
Balanced Capital Allocation 01 02 03 Investing Returning Debt in growth capital repayment Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS T
Slide 6: Accelerating Growth Building Momentum
2026 2027 Building Accelerating Momentum Growth $56–60M $18.5–21M 2026 Revenue 2026 Adj. EBITDA Mid single-digit % growth Relatively flat — driven by CV portfolio absorbing launch costs Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forwar
Slide 7: The Portfolio
The Portfolio NILEMDO / NEXLIZET® the new growth engine Growing VASCEPA® Stable CLOZARIL® base Illustrative purposes only; not financial guidance Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may
Slide 8: Continued Prescribing Growth
VASCEPA® TRx Units (thousands) Since Launch - Canada Continued 180 160 Prescribing 140 120 +17% YTD 2026 units vs YTD 2025 Growth 100 +18% 80 Q2 2026 net sales vs Q2 2025* 60 Patent protection 40 through the late An improving contributor 20 to Adj EBITDA 2030’s 0 2020 2021 2022 2023 2024 2025 * in C
Slide 9: NILEMDO: Strong Launch Quarter, Access Momentum Building
NILEMDO : Strong Launch Quarter, Access Momentum Building Strong first quarter of new-to-brand P RI V A T E P A Y E R C O V E RA G E patients ~80% of eligible privately insured patients now have reimbursement Net Sales Ahead of Forecast P U B L I C R E I M BU R S E M E N T CDA-AMC unanimous positive
Slide 10: NEXLIZET: Building on the NILEMDO Foundation
NEXLIZET®: Building on the NILEMDO Foundation One Pill, Two Mechanisms ~38% LDL-C Reduction¹ A Built-In Second Option Bempedoic acid + A meaningful step up For every physician ezetimibe, with no when statins and already writing NILEMDO added pill burden ezetimibe alone fall short By Year-End 2026 1H
Slide 11: National patient volumes increased 5 straight months
National patient volumes increased 5 straight months 10%+ growth in British Columbia ~50% market share maintained Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims
Slide 12: Q2 2026 Financial Review
Q2 2026 Financial Review Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERAPEUTICS INC. 12
Slide 13: Expect Quarterly Seasonality to Continue in 2026
Expect Quarterly Seasonality to Continue in 2026 Adjusted EBITDA by Quarter (millions) USD $18.5-21M Adj. EBITDA $5.6 $5.7 2026 Guidance $5.2 $4.9 $4.7 $4.3 $4.1 $3.8 $3.5 NILEMDO launch costs $2.7 weighted towards 1H 2026 with Adj. EBITDA margins improving in 2H 2026 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Slide 14: Growing Cash Generation, Declining Debt Service
Growing Cash Generation, Declining Debt Service Cash Generation Trailing Twelve Months (TTM) – USD in millions $16 $14.7 $14 Strong Cash $12 Generation $10 Trend from $8 $8.1 Core Business $6 $4 $2.3 $3.2 $2 $- Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 TTM AEBIT
Slide 15: Stronger Financials Fund Growth and Shareholder Value
Stronger Financials Fund Growth and Shareholder Value 01 02 03 Investing in Growth Returning Capital Debt Repayment Pursuing BD opportunities aligned with NCIB launched June 2026 for up to 1.5M $1.1M principal repayment in Q2 strategic focus, capabilities and resources shares Term loan $42.2M, down
Slide 16: HLS: A Fundamentally Stronger Company
HLS: A Fundamentally Stronger Company 01 02 03 Strengthened Growth Engine Catalysts Ahead Operations & Financials Delivering Strongest balance sheet in years CV portfolio grew ~25% this quarter Private coverage continuing to ramp Consistent cash generation Vascepa sustaining double-digit growth Purs
Slide 17: Q2 2026 Earnings Call – August 12, 2026
Q2 2026 Earnings Call – August 12, 2026